TSRI partners with Sigma-Aldrich to enable commercialization of research
The partnership will fund research and provide day-of-publication access to TSRI researchers' discoveries for the synthesis and analysis of drug candidates, eliminating months from translating chemistry into drug discovery application.
"The hurdles from bench to clinic, what the (National Institutes of Health) calls the 'valley of death', are proving difficult to surmount, leaving numbers of potential therapeutic ideas trapped inside university doors," Amanda Halford, the vice president of academic research at Sigma-Aldrich, said. "To clear these hurdles, it's critical to open a myriad of novel technologies, such as these from TSRI, to the whole translational research community."
Sigma-Aldrich and TSRI will come together to fund the development of novel reagents from six TSRI labs. Sigma-Aldrich will exclusively commercialize the drugs through a master licensing agreement.
"This is the third major deal in our new targeted partnership strategy, following recent agreements with Janssen Pharmaceuticals and Bristol-Myers Squibb," Scott Forrest, the vice president of Business Development at TSRI, said. "These multi-lab, multi-year alliances fund research and infrastructure in areas of mutual interest, creating a win-win situation for moving innovations into the marketplace. We are pleased to partner with the world's leading reagent company to accelerate the commercialization of new research tools for the scientific community."
In 2012, TSRI and Sigma-Aldrich established a partnership to produce a toolkit of ten novel zinc-based salts discovered in a TSRI lab. The toolkit included a difluoromethylation reagent that was immediately adopted by multiple large pharmaceuticals for optimizing lead compounds.
"The partnership with TSRI will enable us to expand our portfolio through new innovations and product development," Eric Green, the executive vice president and president of research at Sigma-Aldrich, said. "We believe this partnership reinforces our strategy of broadening our research portfolio of innovative products and tools used by the translational research community."
Sigma-Aldrich said the partnership was the first of its kind between a reagents company and a research institute.